Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Terminated Phase 3 Interventional

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

NCT00006994
View directory record Official record
Conditions
Cancer-related Problem/Condition, Head and Neck Cancer, Pain
Interventions
glutamine, radiation therapy, l-glutamine placebo
Dietary Supplement · Radiation · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 1, 2026, 2:24 PM EST
Not listed Not applicable Interventional

Improve Functional Health Status in Minority Women With HIV

NCT04315675
View directory record Official record
Conditions
HIV/AIDS
Interventions
Guided Imagery Intervention, Cognitive Power Intervention, Combined Guided Imagery and Cognitive Power Intervention
Behavioral
Lead sponsor
Seton Hall University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Nov 1, 2026, 2:24 PM EST
Recruiting Not applicable Interventional

Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors

NCT06799481
View directory record Official record
Conditions
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Interventions
Aerobic Exercise, Behavioral Intervention, Follow-Up, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training
Other · Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Completed Not applicable Interventional

ARCH II Study (Alcohol Research Center on HIV Study II)

NCT02563574
View directory record Official record
Conditions
Alcohol Consumption, HIV, Motivation
Interventions
Motivational Interviewing, Questionnaire assessment, Neurocognitive assessments, Blood specimens
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
25 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

NCT01146925
View directory record Official record
Conditions
Contrast-Induced Acute Kidney Injury
Interventions
CRMD-001-Deferiprone, Placebo
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Nov 1, 2026, 2:24 PM EST
Recruiting Phase 2 Interventional

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417
View directory record Official record
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Completed Not applicable Interventional

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

NCT06392789
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Insomnia
Interventions
Cognitive Behavior Therapy for Insomnia, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

NCT00004861
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, tacedinaline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Nov 1, 2026, 2:24 PM EST
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Nov 1, 2026, 2:24 PM EST
Not listed Phase 2 Interventional

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

NCT01782170
View directory record Official record
Conditions
Gingivitis, Investigation of Biological Markers of Inflammation
Interventions
Iocide Oral Rinse, Placebo
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 4 Interventional Results available

Pectoralis and Serratus Muscle Blocks

NCT03743194
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Exparel 266 MG Per 20 ML Injection, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional Results available

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

NCT01062425
View directory record Official record
Conditions
Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo Administration, Temozolomide
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
105
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 1, 2026, 2:24 PM EST
Terminated Phase 2 Interventional Results available

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

NCT02087176
View directory record Official record
Conditions
Previously Treated Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Placebo, Antimitotic Agent, pegfiligrastim
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 1, 2026, 2:24 PM EST
Recruiting Phase 3 Interventional

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

NCT06507618
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Tamoxifen, Letrozole, Anastrozole, or Exemestane
Drug
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
6
States / cities
New Haven, Connecticut • Charlottesville, Virginia • Culpeper, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

NCT00626886
View directory record Official record
Conditions
Postoperative Pain, Inguinal Hernia
Interventions
Bupivacaine Collagen Sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Launch II: A Pilot Randomized Control Trial of a Clinic and Clinic Plus Home Intervention for Preschool Obesity

NCT01419951
View directory record Official record
Conditions
Obesity
Interventions
Clinic + Home Behavioral Intervention, Pediatrician Counseling, Clinic Only Behavioral Intervention
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 5 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Nov 1, 2026, 2:24 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Terminated Phase 2 Interventional

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

NCT00283361
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination
Drug · Procedure · Behavioral
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 3 Interventional Results available

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

NCT04596540
View directory record Official record
Conditions
Chronic Gout
Interventions
SEL-212 low-dose, SEL-212 high-dose, Placebo
Drug · Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
19 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
30
States / cities
Clearwater, Florida • DeBary, Florida • Hialeah, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 1, 2026, 2:24 PM EST
Completed Not applicable Interventional Results available

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

NCT00819208
View directory record Official record
Conditions
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
Interventions
exercise intervention, counseling intervention, Educational Intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Fitness testing
Behavioral · Other · Procedure
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 1, 2026, 2:24 PM EST
Completed Phase 2 Interventional

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

NCT01609140
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
MPSK3169A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 1, 2026, 2:24 PM EST